Protalix Biotherapeutics (PLX) 3.28 $PLX
Protalix BioTherapeutics Names Shlomo Yanai as Chairman of the Board of Directors
GlobeNewswire - Thu Jul 24, 7:00AM CDT
Protalix BioTherapeutics, Inc. (NYSE MKT
LX) (TASELX), announced today that it has chosen Mr. Shlomo Yanai as Chairman of the Company's Board of Directors, effective on July 24, 2014. Mr. Zeev Bronfeld, the interim Chairman of the Board, will remain a member of the Board of Directors.
Protalix Announces New Data on ELELYSO(TM) (taliglucerase alfa) Presented at the European Working Group on Gaucher Disease 2014 11th Meeting
GlobeNewswire - Fri Jun 27, 6:00AM CDT
Protalix BioTherapeutics, Inc. (NYSE MKTLX) (TASELX), announced today that new clinical data on ELELYSO (taliglucerase alfa) will be presented at the European Working Group on Gaucher Disease 2014 11th Meeting being held June 25-28 in Haifa, Israel. ELELYSO, the Company's first commercial product, is the first FDA-approved plant cell-based enzyme replacement therapy for Gaucher disease.
Facebook Leads 3 High-Volume Young Gun Stock Leaders
at Investor's Business Daily - Tue Jun 24, 9:29PM CDT
The biggest stock winners typically come from companies that have gone public in the last 15 years. Such companies may have big growth opportunities, and the stocks may enjoy years of accumulation by mutual funds and other big buyers. IBD's Young...
Protalix BioTherapeutics Announces New Data on ELELYSO(TM) (taliglucerase alfa) and Oral GCD to be Presented at the European Working Group on Gaucher Disease 2014 11th Meeting
GlobeNewswire - Mon Jun 23, 6:30AM CDT
Protalix BioTherapeutics, Inc. (NYSE-MKTLX) (TASELX), announced today that new clinical data on ELELYSO(TM) and oral glucocerebrosidase (GCD), or oral GCD (PRX-112), will be presented at the European Working Group on Gaucher Disease 2014 11 Meeting being held June 25-28 in Haifa, Israel, at the Dan Carmel Hotel.
Protalix Drug in Phase IIa Study for Gaucher Disease - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 19, 5:15PM CDT
Protalix BioTherapeutics, Inc. (PLX) has enrolled the first patient in a phase IIa study on PRX-112 (oral GCD) for the treatment of Gaucher disease.
Protalix (PLX) in Focus: Stock Adds 6.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 19, 8:25AM CDT
Protalix (PLX) was a big mover last session, with shares rising over 6% on the day.
Protalix BioTherapeutics Initiates Phase II Study With PRX-112, an Orally-Administered Enzyme Replacement Therapy for the Treatment of Gaucher Disease
GlobeNewswire - Wed Jun 18, 6:30AM CDT
Protalix BioTherapeutics, Inc. (NYSE MKTLX) (TASELX), announced today that the first Gaucher patient has been enrolled in the Company's phase IIa clinical trial of oral glucocerebrosidase (GCD), or oral GCD (PRX-112), for the treatment of Gaucher disease. Oral GCD is the Company's proprietary plant cell expressed form of an active glycosylated glucocerebrosidase enzyme (GCD) that is naturally encapsulated within carrot cells and administered orally. The Company expects the trial to be completed during the third quarter of 2014.
Protalix BioTherapeutics' President and Chief Executive Officer, David Aviezer, Ph.D., Will Retire This Year
GlobeNewswire - Fri Jun 13, 7:00AM CDT
Protalix BioTherapeutics, Inc. (NYSE MKTLX) (TASELX), announced today, that David Aviezer, Ph.D., has decided to retire after almost 12 years from his role as the Company's President and Chief Executive Officer. He will retire this year upon the completion of a process to nominate his successor. In the meantime, Dr. Aviezer will continue serving as President and Chief Executive Officer and remains a member of the Board of Directors.
Protalix wins approval to market ELELYSO (taliglucerase alfa) in Canada for the treatment of Gaucher Disease
M2 - Mon Jun 02, 4:34AM CDT
Biopharmaceutical company Protalix BioTherapeutics (NYSE MKTLX) (Tel AvivLX.TA) reported on Friday the receipt of Health Canada's regulatory approval for ELELYSO for the long-term enzyme replacement therapy for both adult and pediatric patients with a confirmed diagnosis of Type 1 Gaucher disease.
Protalix Announces ELELYSO(TM) (taliglucerase alfa) Approved in Canada for the Treatment of Gaucher Disease in Both Adult and Pediatric Patients
GlobeNewswire - Fri May 30, 6:30AM CDT
Protalix BioTherapeutics, Inc. (NYSE MKTLX) (TASELX), announced today that Health Canada has granted regulatory approval to ELELYSO(TM) (taliglucerase alfa for injection) for the long-term enzyme replacement therapy for both adult and pediatric patients with a confirmed diagnosis of Type 1 Gaucher disease. ELELYSO may also be used for the hematological manifestations in pediatric patients with a confirmed diagnosis of Type 3 Gaucher disease. ELELYSO will be marketed in Canada by Pfizer Inc., the Company's commercialization partner.
Protalix BioTherapeutics to Present at Two Upcoming Healthcare Conferences
GlobeNewswire - Wed May 28, 6:30AM CDT
Protalix BioTherapeutics, Inc. (NYSE MKTLX) (TASELX), today announced that senior management will present at the Jefferies 2014 Global Healthcare Conference and the Wells Fargo Securities Research & Economics 2014 Healthcare Conference. Details regarding the conferences are as follows:
Protalix Announces ELELYSO(TM) (taliglucerase alfa) Approved in Australia for the Treatment of Gaucher Disease in Both Adult and Pediatric Patients
GlobeNewswire - Thu May 22, 6:37AM CDT
Protalix BioTherapeutics, Inc. (NYSE MKTLX) (TASELX), announced today that the Australian Therapeutic Goods Administration (TGA) has granted regulatory approval to ELELYSO(TM) (taliglucerase alfa) for long-term enzyme replacement therapy for both adult and pediatric patients with a confirmed diagnosis of Type 1 Gaucher disease associated with at least one of the following: splenomegaly, hepatomegaly, anemia, thrombocytopenia. ELELYSO will be marketed in Australia by Pfizer Inc., the Company's commercialization partner.
Protalix BioTherapeutics Up 5.1%, Shares Break Through Resistance (PLX)
Comtex SmarTrend(R) - Tue Mar 25, 12:45PM CDT
Protalix BioTherapeutics (AMEXLX) is one of today's best performing low-priced stocks, up 5.1% to $4.76 on 1.1x average daily volume. Protalix BioTherapeutics has traded 246,000 shares thus far today, vs. average volume of 232,000 shares per day. The stock has outperformed the Dow (5.1% to the Dow's 0.7%) and outperformed the S&P 500 (5.1% to the S&P's 0.5%) during today's trading.
Uptrend Call Working As Protalix BioTherapeutics Stock Rises 9.4% (PLX)
Comtex SmarTrend(R) - Fri Mar 07, 11:24AM CST
SmarTrend identified an Uptrend for Protalix BioTherapeutics (AMEXLX) on February 10th, 2014 at $4.67. In approximately 4 weeks, Protalix BioTherapeutics has returned 9.40% as of today's recent price of $5.10.
Godliness and Hard Work
by Adam Hartman - All Africa Global Media - Thu Feb 13, 6:11AM CST
OTJIMBINGWE'S Da-Palm Senior Secondary School's recipe for producing best Grade 12 results is simple - Godliness and hard work - according to the principal.
Protalix BioTherapeutics Announces Oral GCD Data to be Presented at WORLD Symposium 2014
GlobeNewswire - Wed Feb 12, 6:30AM CST
Protalix BioTherapeutics, Inc. (NYSE MKTLX) (TASELX) announced today that phase I clinical trial data for oral GCD (PRX-112) for the treatment of Gaucher disease will be presented by Professor Ari Zimran at the 10th Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2014 being held February 10-13 in San Diego, CA. Oral GCD is the Company's orally-delivered proprietary formulation of the plant cell-expressed enzyme, glucocerebrosidase (GCD), and contains the same active substance as taliglucerase alfa (ELELYSO(TM)), the Company's approved enzyme replacement therapy.
Protalix BioTherapeutics' Technology Transfer Agreement for UPLYSO(TM) (alfataliglicerase) With Brazil's Ministry of Health Approved by the Brazilian National Institute of Industrial Property
GlobeNewswire - Thu Feb 06, 6:30AM CST
Protalix BioTherapeutics, Inc. (NYSE MKTLX) (TASELX), announced today that the Brazilian National Institute of Industrial Property (INPI) has approved the Company's previously-announced supply and technology transfer agreement with Fundacão Oswaldo Cruz (commonly referred to as Fiocruz), an arm of the Brazilian Ministry of Health for UPLYSO(TM) (alfataliglicerase). The Company announced the execution of the supply and technology transfer agreement on June 19, 2013, and receipt of the approval results in the final effectiveness of the agreement as of January 23, 2014. The Company has already completed the first shipment of the drug to Brazil under the agreement.
IHG Opens Crowne Plaza Hotel Near JFK International Airport
M2 - Fri Jan 31, 12:02PM CST
InterContinental Hotels Group has expanded its portfolio of New York hotels with the opening of the Crowne Plaza JFK Airport New York City hotel.
Protalix Announces Successful Manufacturing Facility Evaluation by Health Canada
GlobeNewswire - Thu Jan 23, 3:30PM CST
Protalix BioTherapeutics, Inc. (NYSE MKTLX) (TASELX), announced today that Health Canada has completed a successful on-site evaluation of the Company's manufacturing facility in Carmiel, Israel, as part of its ongoing review of the new drug submission (NDS) for taliglucerase alfa for the treatment of Gaucher disease. The purpose of the on-site evaluation was to verify the facility's compliance with certain Canadian food and drug regulations and, upon completion of the evaluation, Health Canada recommended approval from a facility perspective. A decision on final marketing approval of taliglucerase alfa in Canada is expected during 2014.
3 High-Risk, High-Reward Biotech Stocks for Long Term Investors
Maxx Chatsko, The Motley Fool - Motley Fool - Wed Jan 22, 4:02PM CST
Investors love being early adopters and supporters of innovative and disruptive companies, especially biotech companies, which can yield outsized gains. Unfortunately, it can be difficult to decipher which developmental companies truly have an edge,...
Protalix BioTherapeutics Names Shlomo Yanai as Chairman of the Board of Directors
GlobeNewswire - Thu Jul 24, 7:00AM CDT
Protalix BioTherapeutics, Inc. (NYSE MKT
LX) (TASELX), announced today that it has chosen Mr. Shlomo Yanai as Chairman of the Company's Board of Directors, effective on July 24, 2014. Mr. Zeev Bronfeld, the interim Chairman of the Board, will remain a member of the Board of Directors. Protalix Announces New Data on ELELYSO(TM) (taliglucerase alfa) Presented at the European Working Group on Gaucher Disease 2014 11th Meeting
GlobeNewswire - Fri Jun 27, 6:00AM CDT
Protalix BioTherapeutics, Inc. (NYSE MKT
LX) (TASELX), announced today that new clinical data on ELELYSO (taliglucerase alfa) will be presented at the European Working Group on Gaucher Disease 2014 11th Meeting being held June 25-28 in Haifa, Israel. ELELYSO, the Company's first commercial product, is the first FDA-approved plant cell-based enzyme replacement therapy for Gaucher disease. Facebook Leads 3 High-Volume Young Gun Stock Leaders
at Investor's Business Daily - Tue Jun 24, 9:29PM CDT
The biggest stock winners typically come from companies that have gone public in the last 15 years. Such companies may have big growth opportunities, and the stocks may enjoy years of accumulation by mutual funds and other big buyers. IBD's Young...
Protalix BioTherapeutics Announces New Data on ELELYSO(TM) (taliglucerase alfa) and Oral GCD to be Presented at the European Working Group on Gaucher Disease 2014 11th Meeting
GlobeNewswire - Mon Jun 23, 6:30AM CDT
Protalix BioTherapeutics, Inc. (NYSE-MKT
LX) (TASELX), announced today that new clinical data on ELELYSO(TM) and oral glucocerebrosidase (GCD), or oral GCD (PRX-112), will be presented at the European Working Group on Gaucher Disease 2014 11 Meeting being held June 25-28 in Haifa, Israel, at the Dan Carmel Hotel. Protalix Drug in Phase IIa Study for Gaucher Disease - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 19, 5:15PM CDT
Protalix BioTherapeutics, Inc. (PLX) has enrolled the first patient in a phase IIa study on PRX-112 (oral GCD) for the treatment of Gaucher disease.
Protalix (PLX) in Focus: Stock Adds 6.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 19, 8:25AM CDT
Protalix (PLX) was a big mover last session, with shares rising over 6% on the day.
Protalix BioTherapeutics Initiates Phase II Study With PRX-112, an Orally-Administered Enzyme Replacement Therapy for the Treatment of Gaucher Disease
GlobeNewswire - Wed Jun 18, 6:30AM CDT
Protalix BioTherapeutics, Inc. (NYSE MKT
LX) (TASELX), announced today that the first Gaucher patient has been enrolled in the Company's phase IIa clinical trial of oral glucocerebrosidase (GCD), or oral GCD (PRX-112), for the treatment of Gaucher disease. Oral GCD is the Company's proprietary plant cell expressed form of an active glycosylated glucocerebrosidase enzyme (GCD) that is naturally encapsulated within carrot cells and administered orally. The Company expects the trial to be completed during the third quarter of 2014. Protalix BioTherapeutics' President and Chief Executive Officer, David Aviezer, Ph.D., Will Retire This Year
GlobeNewswire - Fri Jun 13, 7:00AM CDT
Protalix BioTherapeutics, Inc. (NYSE MKT
LX) (TASELX), announced today, that David Aviezer, Ph.D., has decided to retire after almost 12 years from his role as the Company's President and Chief Executive Officer. He will retire this year upon the completion of a process to nominate his successor. In the meantime, Dr. Aviezer will continue serving as President and Chief Executive Officer and remains a member of the Board of Directors. Protalix wins approval to market ELELYSO (taliglucerase alfa) in Canada for the treatment of Gaucher Disease
M2 - Mon Jun 02, 4:34AM CDT
Biopharmaceutical company Protalix BioTherapeutics (NYSE MKT
LX) (Tel AvivLX.TA) reported on Friday the receipt of Health Canada's regulatory approval for ELELYSO for the long-term enzyme replacement therapy for both adult and pediatric patients with a confirmed diagnosis of Type 1 Gaucher disease. Protalix Announces ELELYSO(TM) (taliglucerase alfa) Approved in Canada for the Treatment of Gaucher Disease in Both Adult and Pediatric Patients
GlobeNewswire - Fri May 30, 6:30AM CDT
Protalix BioTherapeutics, Inc. (NYSE MKT
LX) (TASELX), announced today that Health Canada has granted regulatory approval to ELELYSO(TM) (taliglucerase alfa for injection) for the long-term enzyme replacement therapy for both adult and pediatric patients with a confirmed diagnosis of Type 1 Gaucher disease. ELELYSO may also be used for the hematological manifestations in pediatric patients with a confirmed diagnosis of Type 3 Gaucher disease. ELELYSO will be marketed in Canada by Pfizer Inc., the Company's commercialization partner. Protalix BioTherapeutics to Present at Two Upcoming Healthcare Conferences
GlobeNewswire - Wed May 28, 6:30AM CDT
Protalix BioTherapeutics, Inc. (NYSE MKT
LX) (TASELX), today announced that senior management will present at the Jefferies 2014 Global Healthcare Conference and the Wells Fargo Securities Research & Economics 2014 Healthcare Conference. Details regarding the conferences are as follows: Protalix Announces ELELYSO(TM) (taliglucerase alfa) Approved in Australia for the Treatment of Gaucher Disease in Both Adult and Pediatric Patients
GlobeNewswire - Thu May 22, 6:37AM CDT
Protalix BioTherapeutics, Inc. (NYSE MKT
LX) (TASELX), announced today that the Australian Therapeutic Goods Administration (TGA) has granted regulatory approval to ELELYSO(TM) (taliglucerase alfa) for long-term enzyme replacement therapy for both adult and pediatric patients with a confirmed diagnosis of Type 1 Gaucher disease associated with at least one of the following: splenomegaly, hepatomegaly, anemia, thrombocytopenia. ELELYSO will be marketed in Australia by Pfizer Inc., the Company's commercialization partner. Protalix BioTherapeutics Up 5.1%, Shares Break Through Resistance (PLX)
Comtex SmarTrend(R) - Tue Mar 25, 12:45PM CDT
Protalix BioTherapeutics (AMEX
LX) is one of today's best performing low-priced stocks, up 5.1% to $4.76 on 1.1x average daily volume. Protalix BioTherapeutics has traded 246,000 shares thus far today, vs. average volume of 232,000 shares per day. The stock has outperformed the Dow (5.1% to the Dow's 0.7%) and outperformed the S&P 500 (5.1% to the S&P's 0.5%) during today's trading. Uptrend Call Working As Protalix BioTherapeutics Stock Rises 9.4% (PLX)
Comtex SmarTrend(R) - Fri Mar 07, 11:24AM CST
SmarTrend identified an Uptrend for Protalix BioTherapeutics (AMEX
LX) on February 10th, 2014 at $4.67. In approximately 4 weeks, Protalix BioTherapeutics has returned 9.40% as of today's recent price of $5.10. Godliness and Hard Work
by Adam Hartman - All Africa Global Media - Thu Feb 13, 6:11AM CST
OTJIMBINGWE'S Da-Palm Senior Secondary School's recipe for producing best Grade 12 results is simple - Godliness and hard work - according to the principal.
Protalix BioTherapeutics Announces Oral GCD Data to be Presented at WORLD Symposium 2014
GlobeNewswire - Wed Feb 12, 6:30AM CST
Protalix BioTherapeutics, Inc. (NYSE MKT
LX) (TASELX) announced today that phase I clinical trial data for oral GCD (PRX-112) for the treatment of Gaucher disease will be presented by Professor Ari Zimran at the 10th Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2014 being held February 10-13 in San Diego, CA. Oral GCD is the Company's orally-delivered proprietary formulation of the plant cell-expressed enzyme, glucocerebrosidase (GCD), and contains the same active substance as taliglucerase alfa (ELELYSO(TM)), the Company's approved enzyme replacement therapy. Protalix BioTherapeutics' Technology Transfer Agreement for UPLYSO(TM) (alfataliglicerase) With Brazil's Ministry of Health Approved by the Brazilian National Institute of Industrial Property
GlobeNewswire - Thu Feb 06, 6:30AM CST
Protalix BioTherapeutics, Inc. (NYSE MKT
LX) (TASELX), announced today that the Brazilian National Institute of Industrial Property (INPI) has approved the Company's previously-announced supply and technology transfer agreement with Fundacão Oswaldo Cruz (commonly referred to as Fiocruz), an arm of the Brazilian Ministry of Health for UPLYSO(TM) (alfataliglicerase). The Company announced the execution of the supply and technology transfer agreement on June 19, 2013, and receipt of the approval results in the final effectiveness of the agreement as of January 23, 2014. The Company has already completed the first shipment of the drug to Brazil under the agreement. IHG Opens Crowne Plaza Hotel Near JFK International Airport
M2 - Fri Jan 31, 12:02PM CST
InterContinental Hotels Group has expanded its portfolio of New York hotels with the opening of the Crowne Plaza JFK Airport New York City hotel.
Protalix Announces Successful Manufacturing Facility Evaluation by Health Canada
GlobeNewswire - Thu Jan 23, 3:30PM CST
Protalix BioTherapeutics, Inc. (NYSE MKT
LX) (TASELX), announced today that Health Canada has completed a successful on-site evaluation of the Company's manufacturing facility in Carmiel, Israel, as part of its ongoing review of the new drug submission (NDS) for taliglucerase alfa for the treatment of Gaucher disease. The purpose of the on-site evaluation was to verify the facility's compliance with certain Canadian food and drug regulations and, upon completion of the evaluation, Health Canada recommended approval from a facility perspective. A decision on final marketing approval of taliglucerase alfa in Canada is expected during 2014. 3 High-Risk, High-Reward Biotech Stocks for Long Term Investors
Maxx Chatsko, The Motley Fool - Motley Fool - Wed Jan 22, 4:02PM CST
Investors love being early adopters and supporters of innovative and disruptive companies, especially biotech companies, which can yield outsized gains. Unfortunately, it can be difficult to decipher which developmental companies truly have an edge,...
